Warfarin DDI: Clinical Relevance AC-052-352
- Clinical experience in PAH patients (34 placebo and 59 bosentan patients)
- No change in warfarin dose (BL vs end of treatment)
- No change in INR (BL vs end of treatment)
- No difference in warfarin dose changes during treatment vs placebo